Table of contents


On 16 February 2006, orphan designation (EU/3/06/349) was granted by the European Commission to Vectura Group plc, United Kingdom, for apomorphine hydrochloride (inhalation use) for the treatment of off-periods in Parkinson's disease not responding to oral treatment.

The sponsorship was transferred to Vectura Ireland Limited, Ireland in March 2019.

Key facts

Active substance
Apomorphine hydrochloride (inhalation use)
Disease / condition
Treatment of off-periods in Parkinson's disease not responding to oral treatment
Date of first decision
EU designation number

Sponsor's contact details

Vectura Ireland Limited
The Brickhouse
Block 1, Clanwilliam Court
Lower Mount Street
Dublin 2, D02 CF97
Tel. + 353 1541 4798

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating